Skip to main content
. 2011 Nov 19;55(2):489–498. doi: 10.1007/s00125-011-2371-6

Table 1.

Patient details: type 1 diabetes mellitus (n = 18)

Age (years) BMI (kg/m2) Diabetic complications HbA1c (range) Type of insulin Parity Gestational age (weeks) Birthweight (kg) Caesarean indication
% mmol/mol
40 31.6 None 6.1–6.2 43–44 Humulin; humalog 1 38 3.69 Previous CS
40 22.3 None 5.9–6.4 41–46 Humalog; lantus 1 38 3.49 Maternal request
26 28.9 Retinopathy 6.4–6.6 46–49 CSII 0 35+2 2.18 Maternal request
24 30.1 Microalbuminuria 7.9–8.1 63–65 Novorapid, glarginea 0 38 3.34 Previous CS
36 24.6 None 6.0–7.0 42–53 Novorapid, lantus 1 37+4 4.5 Diabetes
CSII
36 22.4 Previous nephropathy 6.5–6.8 48–51 CSII 1 36+4 4.42 Maternal reason
27 41.9 None 7.9–9.7 63–83 Humalog; lantus 2 35+3 4.48 Diabetes
39 30 Retinopathy 6.4–8.2 46–66 Humalog; humulin 0 34+0 2.58 Previous CS/maternal request
44 31.2 Vascular 6.3 45 Insulin 3 36+4 2.72 Maternal reason
29 22.3 None 5.7–6.3 39–45 Insulin 1 38 3.26 Diabetes
28 43 Nephropathy 7.1–7.5 54–59 Novorapid, lantus 3 35+2 4.37 Diabetes
34 43.8 None 6.7 50 Insulin 1 37+1 4.31 Previous CS
37 22.6 Retinopathy 6 42 Novorapid, lantus 3 32+6 2.48 Maternal reason
38 25.2 Hypertension 6.5 48 Novorapid, lantus 3 36+3 4.115 Previous CS
27 24.2 None 5.9 41 CSII 3 33+5 2.46 Breech
41 46.2 Hypertension 6.1 43 Novorapid, lantus 1 37.5 3.29 Previous CS
36 24.8 Retinopathy and nephropathy 5 31 Novorapid, lantus 0 37 3.27 Diabetes
40 36.5 None 5.5–6.0 37–42 Novorapid 2 38 3.75 Previous CS

aInsulin glargine (A21Gly,B31Arg,B32Arg human insulin)